DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression

Information source: Xian-Janssen Pharmaceutical Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depressive Disorder

Intervention: Escitalopram (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Xian-Janssen Pharmaceutical Ltd.

Official(s) and/or principal investigator(s):
Xian-Janssen Pharmaceutical Ltd., China Clinical Trial, Study Director, Affiliation: Xian-Janssen Pharmaceutical Ltd.

Summary

The purpose of this study is to evaluate the efficacy and safety of escitalopram treatment in participants with severe major depressive disorder (MDD [marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation]).

Clinical Details

Official title: A Single-arm, Open-label, Multi-center Study to Investigate Efficacy and Safety of Lexapro on Acute Treatment of Severe Depression

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Participants With Remission Based on Montgomery-Asberg Depression Rating Scale (MADRS)

Secondary outcome:

Percentage of Participants With Clinical Response Based on Montgomery-Asberg Depression Rating Scale (MADRS)

Percentage of Participants With Clinical Onset Based on Montgomery-Asberg Depression Rating Scale (MADRS)

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 1, 2, 4 and 8

Change From Baseline in Hamilton Depression Rating Scale (HAM-D-17) Score at Week 1, 2, 4 and 8

Change From Baseline in Hamilton Anxiety Scale (HAMA) Score at Week 1, 2, 4 and 8

Change From Baseline in Brain-Derived Neurotrophic Factor (BDNF) at Week 8

Change From Baseline in Short Form-12 (SF-12) Score at Week 8

Change from Baseline in Plasma Drug Concentration at Week 1 and 8

Number of Participants with Structural and Functional Changes in Magnetic Resonance Imaging (MRI) at Week 8

Detailed description: This is a single-arm (clinical study in only one group of participants), open-label (all people know the identity of the intervention), multi-center (when more than one hospital or medical school team work on a medical research study), and prospective (study following participants forward in time) study. The study consists of 2 parts: Screening (that is, 5 days before study commences on Day 1) and Treatment (that is, Week 1-8). All the eligible participants will be receiving flexible doses of escitalopram orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Efficacy will primarily be evaluated by remission rate at the end of the study. Participants' safety will be monitored throughout the study.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participants diagnosed with major depressive disorder (MDD) according to Diagnostic

and Statistical Manual of Mental Disorders-IV (DSM-IV)

- Scores of greater than or equal to 30 on the Montgomery-Asberg Depression Rating

Scale (MADRS) Exclusion Criteria:

- Pregnant or lactating female participants

- Participants who are previously or currently diagnosed with the following mental

disorders by DSM-IV: organic mental disorder, schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), schizoaffective disorder, delusional disorder, undifferentiated mental disorders and bipolar affective disorder, participants with history of drug abuse, including alcohol and drug abuse in the past 12 months

- Participants who have significant risk of suicide on clinical assessment (has a score

of greater than or equal to 5 on item 5 of MADRS) or have made a serious suicide attempt within the past 6 months and have any contraindication to escitalopram

- Participants who have known history of serious or unstable medical illness, including

cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease currently taking other psychotropic drugs and anticonvulsant agents or continuously taking benzodiazepines or sleeping pills for over five days in the past one week

- Participants who have history of seizure (sudden, uncontrolled muscle spasms and loss

of consciousness resulting from abnormal brain function) disorder, brain injury, any history of known neurological disease (multiple sclerosis, degenerative diseases, parkinson disease and any movement disorders) and have multiple drug adverse reactions

Locations and Contacts

Beijing, China

Huzhou, China

Nanjing, China

Qingdao, China

Shanghai, China

Wuhan, China

Additional Information

A Single-arm, Open-label, Multi-center Study to Investigate Efficacy and Safety of Lexapro on Acute Treatment of Severe Depression

Starting date: February 2010
Last updated: January 2, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017